SGT-152
CUMYL-NBMINACA or also called SGT-152 is a synthetic cannabinoid, a designer drug developed as a replacement for SGT-151. This substance has a high cannabinoid potency and is an active agonist of the CB1 and CB2 receptors.
You can get acquainted with the prices and buy SGT-152 online right now, at OmniCompound company. We provide all the necessary information about the products and provide a quality guarantee.
Weight | 5g | 10g | 25g | 50g | 100g | 250g | 500g | 1000g |
---|---|---|---|---|---|---|---|---|
Price | €12.00/Per gram | €10.00/Per gram | €7.50/Per gram | €4.30/Per gram | €3.50/Per gram | €2.40/Per gram | €1.90/Per gram | €1.50/Per gram |
$12.00
Enjoy secure shopping, competitive prices, and fast, discreet delivery. Your satisfaction is our priority!
Description
CUMYL-NBMINACA or also called SGT-152 is a synthetic cannabinoid, a designer drug developed as a replacement for SGT-151. This substance has a high cannabinoid potency and is an active agonist of the CB1 and CB2 receptors.
SGT-152 is a designer cannabinoids drug and its toxicological and pharmacological properties are under investigation and not fully understood. This chemical is intended for research and identification of properties, in special rooms, on special laboratory equipment, in compliance with all safety measures.
You can get acquainted with the prices and buy SGT-152 online right now, at OmniCompound company. We provide all the necessary information about the products and provide a quality guarantee.
CAS | 1631074-60-6 |
Product Name | CUMYL-NBMINACA, SGT-152 |
Molecular Formula | C25H29N3O |
Molecular Weight | 387.5 |
IUPAC Name | 1-(bicyclo[2.2.1]hept-2-ylmethyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide |
InChI | InChI=1S/C18H26N4O2/c1-5-6-11-22-13-10-8-7-9-12(13)14(21-22)17(24)20-15(16(19)23)18(2,3)4/h7-10,15H,5-6,11H2,1-4H3,(H2,19,23)(H,20,24)/t15-/m1/s1 |
Solubility |
|
Synonyms | CUMYL-NBMINACA, SGT-152 |
Purity | ≥98% |
Formulation | A crystalline solid, Powder |
Storage | -20°C |
Stability | ≥ 2 years |
Quick Inquiry